Neoplasm Metastasis  >>  odanacatib (MK-0822)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT00691899 / 2008-002120-29: A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030)

Withdrawn
3
0
US
odanacatib, MK0822, placebo (unspecified)
Merck Sharp & Dohme LLC
Prostate Cancer
09/08
09/08
NCT00692458 / 2008-002119-42: A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

Withdrawn
3
0
US
Comparator: odanacatib, Comparator: placebo
Merck Sharp & Dohme LLC
Breast Cancer
09/08
09/08

Download Options